## RAS specific protease Induces Irreversible Growth Arrest via p27 in several KRAS Mutant Colorectal Cancer cell lines

Caleb K. Stubbs, Marco Biancucci\*, Vania Vidimar\*, Karla J. F. Satchell†

Department of Microbiology and Immunology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.

\*Present addresses: M.B., GSK Vaccines, Rockville, MD 20850, USA; V.V., Merck Research Laboratories, Boston, MA 02115

**†Corresponding author:** Karla Satchell, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA. Email: k-satchell@northwestern.edu



**Supplementary Figure 1**. Growth inhibition of RAS-less MEFs cell lines. (**A-H**) Growth inhibition observed in of RAS-less MEF cell lines at indicted timepoints following treatment with PA alone or in combination with  $LF_NRRSP$  or  $LF_NRRSP^*$ ; n = 3. Results are expressed as ± SEM.



а

**Supplementary Figure 2**. Growth inhibition in RRSP-DT<sub>B</sub> treated CRC cell lines. (**A**). Western blot analysis of HB-EGF receptor (DT receptor) from untreated CRC cell line lysates. Vinculin was used as loading control. (**B-I**) Cell growth over time was monitored by time lapse video microscopy and quantified using Nikon Elements to calculate cell confluency. Fitted dose response curve of RRSP-DT<sub>B</sub> in CRC cell lines show relative confluency compared to PBS values after 48 and 72 hours. Results are displayed as mean  $\pm$  SEM, n = 4. (**J**) Representative brightfield images of CRC cell lines treated with either RRSP-DT<sub>B</sub> or RRSP\*-DT<sub>B</sub> (0.1 nM) after 24 hours.



**Supplementary Figure 3**. Heatmap of human phospho-kinase array in HCT-116 and SW620 cells treated RRSP-DT<sub>B</sub> treated samples. Densitometric analysis of phospho-kinase array depicted through a heatmap of relative phosphorylated proteins levels in response to 10 nM RRSP-DT<sub>B</sub> compared to PBS control in HCT-116 and SW620 cells after 24 hr.



b



С

**Supplementary Figure 4**. Total RB expression in CRC cell lines. (**A**) Representative images of HCT-116 cells transfected with pGFP-RB after 24 hr (**B**) Western blot analysis of HCT-116 cells transfected with GFP tagged RB following treatment with either PBS, RRSP-DT<sub>B</sub> or RRSP\*-DT<sub>B</sub> after 24 hours. Total RB was detected using anti-GFP primary antibody.  $\alpha$ Tubulin was used as a gel loading control. (**C**) Western blot analysis of p21 levels in GP5d cell treated with either PBS, RRSP-DT<sub>B</sub> or RRSP\*-DT<sub>B</sub> after 24 hr.



**Supplementary Figure 5**. Cell cycle analysis of CRC cell lines treated RRSP-DT<sub>B</sub>. (**A-D**) Representative flow cytometry plots of CRC cell lines treated with either PBS, RRSP-DT<sub>B</sub> or RRSP\*-DT<sub>B</sub> (1 nM) after 24 hours. Gating parameters were used to only collect single live cell populations.



Supplementary Figure 6. Cell cycle analysis of RRSP-DT<sub>B</sub> treated CRC cell lines. (A-D) Quantitative analysis of cell cycle analysis of CRC cell lines treated with PBS, 1 nM RRSP-DT<sub>B</sub> or 1 nM RRSP\*-DT<sub>B</sub> for 24 hours; n = 3. Results are expressed as means ± SEM of three independent experiments (\*P< 0.05, \*\*P<0.01, \*\*\*\*P<0.0001 versus PA control as determined through one-way ANOVA followed by Dunnett's multiple comparison test).



**Supplementary Figure 7**. Uncropped immunoblots for Fig 1A (A). Lanes from main figure are shown within rectangle. Membrane was stripped and reprobed for target proteins sharing similar molecular weights.



С







d





**Supplementary Figure 8**. Uncropped immunoblots for Fig 2F (A-D); (A) HCT-116 (B) SW1463 (C) SW620 (D) GP5d. Lanes from main figure are shown within rectangle. Membrane was stripped and reprobed for target proteins sharing similar molecular weights.



**Supplementary Figure 9**. Uncropped immunoblots for Fig 4C (A-D); (A) HCT-116 (B) SW1463 (C) SW620 (D) GP5d. Lanes from main figure are shown within rectangle. Membrane was stripped and reprobed for target proteins sharing similar molecular weights.



**Supplementary Figure 10**. Uncropped immunoblots for Supplementary Fig 2A. Lane 2: HCT-116. Lane 3: SW1463. Lane 4: SW620. Lane 5: GP5d.



**Supplementary Figure 11**. Uncropped immunoblots for Supplementary Fig 4B. Membrane was stripped and reprobed for target proteins sharing similar molecular weights.



**Supplementary Figure 12**. Uncropped immunoblots for Supplementary Fig 4C. Lanes from main figure are shown within rectangle. Membrane was stripped and reprobed for target proteins sharing similar molecular weights.